



Tuesday, 15 May 2018

Break
08:00 - 09:30

Foyer

Registration and Welcome Coffee

Plenary Session
09:30 - 10:00

Congress Hall

Welcome Address

CIMT President Christoph Huber

09:30 - 10:00

Plenary Session
10:00 - 11:30

Congress Hall

Cellular Therapy

Chair: Harpreet Singh (Immatics Biotechnologies, Houston, United States)

New modes of T-cell cancer recognition by dissection of immunotherapy successes

10:00 - 10:30

Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom)

ADAPting to solid tumors, advances and challenges for TCR T-cell therapy

10:30 - 11:00

Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States)

TIL therapy in melanoma: history of clinical development, current status and plans for the future

11:00 - 11:30

Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center, Houston, United States)

Break
11:30 - 13:30

Foyer

Lunch

Corporate Supported Symposium
12:00 - 13:00

Congress Hall

"Immunooncology 2018 and beyond" supported by Bristol-Myers Squibb

Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Immunooncology from mono- to combination therapy - a clinical perspective	12:00 - 12:20
Speaker: Viktor Grünwald (Medical School Hannover (MHH), Hanover, Germany)	
Resistance to immunotherapy	12:20 - 12:40
Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg, Germany)	
Biomarkers in immunooncology - can we predict the outcome of therapy?	12:40 - 13:00
Speaker: Andreas Jung (Ludwig-Maximilians-Universität, Munich, Germany)	

Plenary Session
13:30 - 15:00

Congress Hall

Counteracting Immune Escape

Chair: Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)
Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

TNFR family members and cancer immunotherapy: lessons from chronic infection	13:30 - 14:00
Speaker: Tania Watts (University of Toronto, Toronto, Canada)	
Role of lymphatic vessels in shaping the tumor immune microenvironment	14:00 - 14:30
Speaker: Melody Swartz (University of Chicago, Chicago, United States)	
Regulation of dendritic cells in tumors	14:30 - 15:00
Speaker: Jan P. Böttcher (Technical University Munich, Munich, Germany)	

Break
15:00 - 16:00

Foyer

Coffee Break

Poster Session
15:30 - 18:00

East and West Foyers

Poster Session - Therapeutic Vaccination

Reinforcing dendritic cells for cancer immunotherapy: diverse ways and means to target antigens to human skin
Speaker: Lydia Bellmann (Medical University of Innsbruck, Innsbruck, Austria)
A versatile, high-throughput HLA peptidomics pipeline for cancer neoepitope discovery
Speaker: Leon Bichmann (Uni-Tuebingen, Tuebingen, Germany)
Targeted LC-MS detection identifies novel immunogenic HLA-A2-restricted T cell epitopes derived from HPV16 E6 and E7
Speaker: Maria Bonsack (German Cancer Research Center (DKFZ), Heidelberg, Germany)
Predicting observed patient responses to a short-peptide cancer vaccine via clinical trial simulations
Speaker: Liam V Brown (University of Oxford, Oxford, United Kingdom)
The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successful clinical translation of mutated peptide vaccination
Speaker: Valesca Bukur (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients

Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Dendritic cell-targeted nano-vaccines synergize with anti-PD-1/anti-OX40 for melanoma treatment

Speaker: Joao Conriot (Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal)

Molecular mechanism of immune cell activation by therapeutic melanoma vaccine

Speaker: Patrycja Czerwińska (Poznań University of Medical Sciences, Poznań, Poland)

A cancer vaccine targeting many neo-antigens is required for efficient eradication of large tumors

Speaker: Maria De Lucia (University of Naples Federico II, Naples, Italy)

Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project

Speaker: Katrin Frenzel (BioNTech Group, Mainz, Germany)

Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes

Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)

E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies

Speaker: Christian Grunwitz (Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany)

A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors

Speaker: Maria Hinterberger (Bavarian Nordic, Planegg, Germany)

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma

Speaker: Robert A. Jabulowsky (BioNTech AG, Mainz, Germany)

Novel linear doggybone™ DNA vaccine induces anti-tumour immunity via STING and independent of TLR9

Speaker: Cinderella Jawahar (University of Southampton, Southampton, United Kingdom)

Nucleic Acid based TRL ligand loaded nanocomplexes act as standalone antitumor agents

Speaker: G. Gokberk Kaya (Bilkent University, Ankara, Turkey)

Discovery and vaccine development for hepatocellular carcinoma - HEPAVAC

Speaker: Markus W. Löffler (University of Tübingen, Tübingen, Germany)

Retrospective analysis of neoantigen prediction methods

Speaker: Martin Löwer (TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany)

Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform

Speaker: Heinz Lubenau (VAXIMM GmbH, Mannheim, Germany)

Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice

Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)

The immunopeptidomic landscape of breast cancer

Speaker: Ana Marcu (University of Tuebingen, Tuebingen, Germany)

Multivalent polymeric nanoparticles for combinatorial innovative colorectal cancer immunotherapy and immunomodulation

Speaker: Ana Isabel Matos (Instituto de Investigação do Medicamento (iMed.Ulisboa), Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal)

Ibrutinib in combination with T-cell based immunotherapy in chronic lymphocytic leukemia (CLL) - mass spectrometry-based HLA ligandome analysis of primary CLL cells approves stable presentation of leukemia-associated antigens

Speaker: Annika Nelde (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Nanoparticle-based vaccine improved OX40 anti-tumor efficacy in breast cancer

Speaker: Carina Peres (Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal)

Analysis of the human tumor HLA peptidome based on patient derived xenografts in mice

Speaker: Nataly Rijensky (Technion-Israel Institute of Technology, Haifa, Israel)

Pseudocowpox (PCPV): a viral vector for cancer immunotherapy

Speaker: Karola Rittner (Transgene, Illkirch-Graffenstaden, France)

Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors

Speaker: Nadja Salomon (TRON, Mainz, Germany)

Standard therapy supplemented with immunogenic cell death therapy during and subsequent multimodal immunotherapy for GBM

Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines

Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells

Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

Exosomes co-encapsulating antigen and immunoadjuvants act as an effective therapeutic cancer vaccine

Speaker: Muzaffer Yildirim (Bilkent University, Ankara, Turkey)

Poster Session
15:30 - 18:00

East and West Foyers

Poster Session - Immunomonitoring

Evaluation of immunological changes induced by primary treatment in ovarian cancer patients

Speaker: Thuy Linh Eline Achten (Katholieke Universiteit Leuven, Leuven, Belgium)

Prognostic relevance of immunological changes during first line treatment in epithelial ovarian carcinoma

Speaker: Thaïs Baert (KU Leuven, Leuven, Belgium)

Peripheral blood NKT-cell frequencies and their PD-1 expression levels identify stage IV melanoma patients with poor overall survival under PD-1/CTLA-4 blockade

Speaker: Jonas Bochem (University Medical Center Tübingen, Tübingen, Germany)

T cell Elispot proficiency panel 2017/2018: Evaluating routine T cell Elispot assays

Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

MHC class II Dextramers - A new tool for detection of antigen specific CD4+ T-cells

Speaker: Liselotte Brix (Immudex, Copenhagen, Denmark)

High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive cells

Speaker: Carla Costa-Nunes (Translational Tumor Immunology Group, Department of fundamental Oncology, University of Lausanne, Epalinges, Switzerland)

Rapid Target Identification for T-Cell Immune Responses with SpotMix™ Peptide Pools

Speaker: Maren Eckey (JPT Peptide Technologies GmbH, Berlin, Germany)

MemoMAB: Gateway to human antibody repertoires

Speaker: Christoph Esslinger (Memo Therapeutics AG, Zurich, Switzerland)

CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study

Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)

High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes

Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)

Tumor infiltrating T cells: complete workflows allow faster and improved flow cytometric analysis of syngeneic mouse tumors

Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

New and reproducible method for rapid, standardized PBMC preparation and cryoconservation within the scope of clinical trials

Speaker: Anne Richter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Conventional and immune therapies influence the immune microenvironment of malignant brain tumors

Speaker: Matteo Riva (KU Leuven, Leuven, Belgium)

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

An improved in vitro assay for monitoring antigen-specific T cell responses using synthetic 20mer peptides

Speaker: Juliane Schneider (University of Tübingen, Tübingen, Germany)

The spleen functions as a window of a systemic response to detect responders to immune checkpoint inhibitor treatment in murine progressed solid carcinomas by [18F]FDG positron emission tomography (PET)

Speaker: Barbara F. Schoerg (Eberhard Karls University Tuebingen, Tuebingen, Germany)

Metabolic profiling of secondary lymphatic organs using 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/CT together with eosinophil blood count, S100 and LDH levels is applicable to stratify patients with metastatic melanomas responding to checkpoint inhibitor immunotherapy (CIT)

Speaker: Johannes Schwenck (Eberhard Karls University Tuebingen, Tübingen, Germany)

Development of an imperacer (Immuno-PCR) assay combining broad assay range and excellent sensitivity to support development of a TNF-receptor agonist antibody drug

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Ultra sensitive PK bioanalysis in support of the development of a bi-specific immune-recruiting biotherapeutic

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Bioanalytical PK support for Immunotherapeutics: case studies

Speaker: Mark Spengler (Chimera Biotec, Bremen, Germany)

Finally, empty HLA class I proteins! A disulfide-stabilized variant of HLA-A*02:01

Speaker: Sebastian Springer (Jacobs University Bremen, Bremen, Germany)

Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells

Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)

Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS

Speaker: Alexander Ulges (Immatics Biotechnologies GmbH, Tübingen, Germany)

Scalable end-to-end immune repertoire analysis: the ImmunoGenomiX Platform

Speaker: Henk Jan van den Ham (Enpicom, 's Hertogenbosch, Netherlands)

Tumor epitope detection in monocytes (EDIM) as a marker for antitumoral activity of Newcastle disease virus infusion and modulated electrohyperthermia

Speaker: Stefaan Van Gool (IOZK, Köln, Germany)

Peripheral blood $\gamma\delta$ T-cell frequencies correlate with overall survival of stage IV melanoma patients under PD-1 blockade

Speaker: Kilian Wistuba-Hamprecht (University Medical Center Tübingen, Tübingen, Germany)

Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy

Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)

Poster Session
15:30 - 18:00

East and West Foyers

Poster Session - Tumor Biology and Interaction with the Immune System

Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model

Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

CD47 expression predicts efficacy of macrophage-mediated phagocytosis of tumor cells

Speaker: Kira Böhmer (Crown Bioscience Inc., San Diego, United States)

The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas

Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

Tumoral MHC class II expression in gliomas

Speaker: Lukas Bunse (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Role of 14F7 monoclonal antibody immunoreactivity against N-glycolyl GM3 ganglioside in colon cancer prognostic

Speaker: Adanays Calvo (National Institute of Oncology and Radiobiology, Havana, Cuba)

Human recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) produced by Lactococcus lactis bacteria acts synergistically with 5-Fluorouracil and Metformin to induce apoptosis in colon cancer cells in vitro

Speaker: Katarzyna Ciacma (Jagiellonian University Medical College, Kraków, Poland)

Protumoral effects of TLR7 in lung tumors

Speaker: Isabelle Cremer (INSERM UMRS1138, Paris, France)

Durable response to PD-1 blockade in a patient with mismatch repair deficient advanced biliary tract cancer

Speaker: Elena Czink (National Centre for Tumor Diseases, Heidelberg, Germany)

Dominant oncolysis in a syngeneic lung cancer model treated with LCMV-GP - pseudotyped vesicular stomatitis virus

Speaker: Krishna Das (Medical University Innsbruck, Innsbruck, Austria)

A 3D image-based quantification of tumor-immune cell interactions in the presence of immuno-modulators

Speaker: Lidia Daszkiewicz (Ocello, Leiden, Netherlands)

Targeting Stat3 oncogene addiction together with anti PD-1 antibodies as an effective combination for cancer immunotherapy

Speaker: Mara De Martino (IBYME-CONICET, Buenos Aires, Argentina)

Epigenetic modifications upregulate PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoint genes in breast tumor microenvironment

Speaker: Eyad Elkord (Qatar Biomedical Research Institute, Doha, Qatar)

CD200 mimetic PEG-M49 and doxorubicin co-treatment increases CD4CD8 double positive cells in CD200R1 knockout mice and the levels correlate with its anti tumoral effects

Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

The effects of TRPV1 agonists on immune response to metastatic breast cancer as well as on tumor growth and metastasis

Speaker: Nuray Erin (Akdeniz University, Antalya, Turkey)

VSV-GP therapy is effective in HNSCC though direct tumor lysis and stimulation of an anti-tumor immune response

Speaker: Patrik Erlmann (ViraTherapeutics, Innsbruck, Austria)

Adipose tissue drives accumulation and activation of mast cells in human cancer specimens

Speaker: Dyke Ferber (National Center for Tumor Diseases (NCT), Heidelberg, Germany)

IL27R α deficiency alters stromal cell architecture and delays tumor growth in a polyoma middle T oncoprotein-driven breast cancer model

Speaker: Annika Fink (Goethe-University Frankfurt, Frankfurt, Germany)

Induction of myeloid-derived suppressor cells via tumor-derived extracellular vesicles in malignant melanoma

Speaker: Viktor Fleming (German Cancer Research Center (DKFZ), Heidelberg, Germany)

The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy

Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)

Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells

Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

c-MET dependent neutrophil responses limit cancer immunotherapy

Speaker: Nicole Glodde (University of Magdeburg, Magdeburg, Germany)

The association between the local immunological microenvironment and the local microbiome in colorectal cancer liver metastases

Speaker: Silke Grauling-Halama (National Center for Tumor Diseases, Heidelberg, Germany)

MDSC and neutrophil recruitment and function in melanoma primary and metastatic lesions

Speaker: Christopher Groth (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany)

Size matters: The novel immune checkpoint CEACAM1-3S isoform drives NK cell-mediated cytotoxicity and overall survival in melanoma patients

Speaker: Iris Helfrich (Medical Faculty, University Duisburg-Essen, Essen, Germany)

Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells

Speaker: Dana Hoser (Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany)

Role of tumor-derived extracellular vesicles in immunosuppression in malignant melanoma patients

Speaker: Xiaoying Hu (Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany, Mannheim, Germany)

Targeting CD70-positive cancer associated fibroblasts to tackle the immune suppressive tumor microenvironment in colorectal cancer

Speaker: Julie Jacobs (University of Antwerp, Wilrijk, Belgium)

The macrophage immune checkpoint CD47 is a direct target of EMT transcription factors SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT

Speaker: Bassam Janji (Luxembourg Institute of Health, Luxembourg, Luxembourg)

Therapy resistance in renal cell carcinoma correlates with an endothelial cell dependent altered immune cell infiltrate

Speaker: Eva Juengel (Universitätsmedizin Mainz, Mainz, Germany)

B cells and the antibody response in melanoma: mechanisms of immune modulation and translational opportunities

Speaker: Sophia N Karagiannis (King's College London, London, United Kingdom)

In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination

Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

Indoleamine 2,3-dioxygenase 1 (IDO1) in human T cells is inducible upon T cell activation and type I interferons

Speaker: Raphael Tobias Kfuri Rubens (Ludwig-Maximilians Universität München, Munich, Germany)

RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer

Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

Cytomegalovirus infection leads to c-MET overexpression, adversely affecting survival and resistance to Temozolomide in glioblastoma

Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

Investigating the feasibility of tumour infiltrating lymphocyte therapy for paediatric malignancies with high risk and poor prognosis

Speaker: Gray Kueberuwa (University of Manchester, Manchester, United Kingdom)

Omental fat in ovarian cancer induces lymphangiogenesis

Speaker: Benedicte Lenoir (University Heidelberg, Heidelberg, Germany)

Pancreatic tumor-derived factors induce expansion of myeloid cells with high suppressive capacity

Speaker: Philipp Metzger (Klinikum der Universität München, München, Germany)

Investigation of ICOS expression on human and mouse T cell subsets

Speaker: Ramona Murr (Roche Innovation Center Zurich, Schlieren-Zuerich, Switzerland)

Acute myeloid leukemia (AML) promotes generation of iTregs

Speaker: Anya Nikolai (Loyola University Chicago, Maywood, United States)

Urokinase type Plasminogen Activator and Beta-galactoside alpha 2,6 sialyltransferase 1 found in cancer cell exosomes cause autocrine release of CXCR2 ligands

Speaker: Nur Ogan (Akdeniz University, Antalya, Turkey)

Investigation of effects of MSCs on immunoevasive adaptations of breast tumor cell lines, MDA-MB-231 and MCF-7

Speaker: Alper Tunga Özdemir (Ege University, Institute of Health Sciences, Izmir, Turkey)

The effects of mesenchymal stem cell on the macrophage phenotype

Speaker: Bilge Özdemir (Manisa State Hospital, Manisa, Turkey)

Expression of MHC class I determines the prognostic benefit of tumor-infiltrating T cells in ovarian cancer independent of the PD-1/PD-L1 axis

Speaker: Sterre Paijens (University of Groningen, Groningen, Netherlands)

Uncovering miRNAs that affect melanoma cell recognition and killing by antigen specific CD8+ T cells

Speaker: Antonino A. Pane (DKFZ, Heidelberg, Germany)

Manipulation of potassium channels in tumor specific T cells for improved functionality in the suppressive tumor microenvironment

Speaker: Sara Ram Pedersen (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

Evidence for T-cell mediated immunity of HPV vaccination by 3-colour fluorescent EliSpot assay

Speaker: Rosemarie Preyer (GenID GmbH, Straßberg, Germany)

Upregulation of HLA class I expression, CIITA-related block of HLA class II expression and heterogenous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches

Speaker: Elise Ramia (University of Insubria, Varese, Italy)

Live-cell assays for immune cell killing of 3D tumour spheroids

Speaker: Annedore Respa (Essen Bioscience, Welwyn Garden City, United Kingdom)

The Role of RAF-MAPK signalling in Dendritic cells

Speaker: Kristina Riegel (Mainz University Medical Center/MSU-FZI, Mainz, Germany)

The anatomical location determines type of lymphocyte infiltration in tumors of same etiology

Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)

Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis

Speaker: Tamer Basel Shabaneh (Geisel School of Medicine at Dartmouth, Lebanon, United States)

Pan-cancer analysis of human endogenous retrovirus expression reveals markers for prognosis and immunotherapy response in clear cell renal carcinoma

Speaker: Christof Chiu Smith (UNC - Chapel Hill, Chapel Hill, United States)

Omental fat-induced immune alterations during metastatic spreading of epithelial ovarian cancer: insights from tissue explant culture

Speaker: Meggy Suarez-Carmona (University Hospital Heidelberg, Heidelberg, Germany)

Characterization of rarely detectable tumor-associated antigens (TAA)-specific CD8+ T cells in HCC patients

Speaker: Catrin Tauber (University Hospital Freiburg, Freiburg, Germany)

Increased replication and spread of the oncolytic VSV-GP in a syngeneic prostate cancer model does not correlate with improved therapeutic outcome

Speaker: Carles R. Urbiola (Medical University Innsbruck, Innsbruck, Austria)

Myeloid derived suppressor cells (MDSC) determine outcome in ovarian cancer

Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

Molecular mechanisms responsible for CCR5 regulation on MDSC in melanoma

Speaker: Rebekka Weber (University Medical Center Mannheim, Mannheim, Germany)

Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma

Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

History of prior immunotherapy changes relationship between tumor mutations and TIL repertoire

Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Plenary Session
18:00 - 19:00

Congress Hall

Keynote Lecture

Chair: Christoph Huber (CIMT, Mainz, Germany)

Highly multiplex 2D and 3D imaging of the immune system and tumors

18:00 - 19:00

Speaker: Ronald Germain (NIAD, NIH, Bethesda, United States)

Plenary Session
08:00 - 09:30

Congress Hall

Tumor Microenvironment

Chair: Viktor Umansky (German Cancer Research Center DKFZ, Heidelberg, Germany)
Chair: Günter Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Potent and durable tumor immunity induced by ADU-S100, a first-in-class STING agonist 08:00 - 08:30

Speaker: Andrea van Elsas (Aduro Biotech, Oss, Netherlands)

The Ying and Yang of TAM: Macrophages as effector cells for cytotoxic antibodies in vivo 08:30 - 09:00

Speaker: Falk Nimmerjahn (Friedrich-Alexander-University, Erlangen, Germany)

Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells 09:00 - 09:30

Speaker: Vincenzo Bronte (University of Verona, Verona, Italy)

Break
09:30 - 10:00

Foyer

Coffee Break

Short Talk Session
10:00 - 11:30

Congress Hall

Short Talk Session I Tumor Biology and Interaction with the Immune System

Chair: Hansjörg Schild (Institute for Immunology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)
Chair: Steve Pascolo (University Hospital Zurich, Zurich, Switzerland)

Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model 10:00 - 10:15

Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas 10:15 - 10:30

Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells 10:30 - 10:45

Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination 10:45 - 11:00

Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer 11:00 - 11:15

Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma **11:15 - 11:30**
Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Short Talk Session
10:00 - 11:30

Gutenberg Hall A

Short Talk Session II Cellular Therapy

Chair: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)
Chair: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes **10:00 - 10:15**
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors **10:15 - 10:30**
Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes **10:30 - 10:45**
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells **10:45 - 11:00**
Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples **11:00 - 11:15**
Speaker: Heiko Schuster (Immatics Biotechnologies GmbH, Tübingen, Germany)

Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells **11:15 - 11:30**
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Short Talk Session
10:00 - 11:30

Gutenberg Hall B

Short Talk Session III New Targets & New Leads

Chair: John Castle (Agenus Inc, Lexington, United States)
Chair: Angelika Riemer (German Cancer Research Center DKFZ, Heidelberg, Germany)

Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches **10:00 - 10:15**
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens **10:15 - 10:30**
Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo **10:30 - 10:45**
Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity	10:45 - 11:00
Speaker: Phillip Schiele (GlycoTope GmbH, Berlin, Germany)	
Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification	11:00 - 11:15
Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)	
Theranostic tumor imaging of neuroblastoma using radiolabeled αCD276-antibody	11:15 - 11:30
Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)	

Break
11:30 - 14:00

Foyer

Lunch

Plenary Session
12:00 - 13:30

Congress Hall

CAR T-Cell Therapy organized by CARAT

Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)
Chair: Andrew Kaiser (Miltenyi Biotech, Bergisch Gladbach, Germany)

Chimeric antigen receptor T cells: advances in cellular engineering and clinical development	12:00 - 12:30
Speaker: Bruce Levine (University of Pennsylvania, Philadelphia, United States)	
T-cell engineering for cancer applications	12:30 - 13:00
Speaker: Martin Pule (University College London, London, United Kingdom)	
Cell therapy between academic research and company driven drug development	13:00 - 13:30
Speaker: Peter Borchmann (University Hospital of Cologne, Cologne, Germany)	

Plenary Session
14:00 - 15:30

Congress Hall

Combination Therapies

Chair: Sjoerd H. van der Burg (Leiden University Medical Center, Leiden, Netherlands)
Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Stromal activation in cancer immunology and immunotherapy	14:00 - 14:30
Speaker: Shannon Turley (Genentech, San Francisco, United States)	
Mechanistic insights into the immune adjuvant effect of radiotherapy	14:30 - 15:00
Speaker: Sandra Demaria (Weill Cornell Medical College, New York, United States)	
The anti-TGFβ neutralizing antibody, SAR439459, blocks immunosuppression and exhibits anti-tumor activity in combination with anti-PD1	15:00 - 15:30
Speaker: Jack Pollard (Sanofi Oncology, Cambridge, United States)	

Coffee Break

Poster Session - Cellular Therapy

The CliniMACS Prodigy® and CliniMACS® Electroporator platforms enable automated and GMP-compliant production of dendritic cell vaccines

Speaker: Caroline Angerer (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany)

The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes

Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

LP-141 CliniMACS Prodigy System: primary cross-presenting DCs for the generation of cancer vaccines

Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Automated cell processing and electroporation for generation and genetic engineering of monocyte-derived dendritic cells

Speaker: Eva Bergschneider (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Exploring human T lymphocytes redirected to the tumor neoantigen EGFRvIII for adoptive cellular immunotherapy of non-small cell lung cancer

Speaker: Anita Bhatti (University Medical Center Mainz, Mainz, Germany)

The development of human $\gamma\delta$ -T antigen presenting cells as a clinical grade cancer vaccine

Speaker: Miroslava Blahova (University of Birmingham Medical School, Birmingham, United Kingdom)

In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells

Speaker: Sarah Bonte (Ghent University, Ghent, Belgium)

Automated ex vivo expansion of low numbers of tumor-reactive T cells on the CliniMACS Prodigy®

Speaker: Elvira Criado-Moronati (Miltenyi Biotec, Bergisch Gladbach, Germany)

Nanobody based dual specific CARs

Speaker: Stijn De Munter (Ghent University, Gent, Belgium)

Molecular mechanisms regulating TCR affinity-improved T cells against the NY-ESO-1 tumor antigen

Speaker: Efe Erdes (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

Balancing CD28 costimulation and CD3 ζ activation in CD19 CAR T cells enhances therapeutic potency by delaying T cell differentiation and exhaustion

Speaker: Judith Feucht (Memorial Sloan Kettering Cancer Center, New York City, United States)

Selecting CD8-specific DARPins for T lymphocyte-directed gene delivery

Speaker: Annika Melanie Frank (Paul Ehrlich Institute, Langen, Germany)

The effect of anti-CTLA-4 blockade on the expansion of tumor-infiltrating lymphocytes for adoptive cell therapy in metastatic ovarian cancer

Speaker: Christina Friese (Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, Herlev, Denmark)

In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors

Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

Intracerebral immunomodulation using genetically engineered mesenchymal stem cells induces long-term survival and immunity in glioblastoma

Speaker: Daniela Hirsch (apceth Biopharma GmbH, Munich, Germany)

Affinity maturation and validation of a COL6A3-002-specific T cell receptor for improving performance in adoptive cell therapy

Speaker: Meike Hutt (Immatix Biotechnologies GmbH, Tuebingen, Germany)

CD4 T-cell based immunotherapy of cancer

Speaker: Else Marit Inderberg (Oslo University Hospital- The Norwegian Radium Hospital, Oslo, Norway)

Substantially enhanced CAR-gene transfer rates by CD4- and CD8-targeted lentiviral vectors while retaining selectivity

Speaker: Arezoo Jamali (Paul Ehrlich Institute, Langen, Germany)

Best chimeric antigen receptor (CAR) expressing vehicle: peripheral versus tumour infiltrating lymphocytes

Speaker: Milena Kalaitidou (University of Manchester, Manchester, United Kingdom)

Adoptive immunotherapy using DNA-demethylated Th-cells as antigen presenting cells induces tumor regression in patients with relapsed glioblastoma

Speaker: Alexei F. Kirkin (CytoVac A/S, Hørsholm, Denmark)

Selective bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor therapy

Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of cancer

Speaker: Sebastian Kobold (Klinikum der Universität München, München, Germany)

Murine-human hybrid tyrosinase reactive T-cell receptor increases antigen reactivity and cytokine production

Speaker: Yi Wei Lim (Loyola University Chicago, Chicago, United States)

PD-L1-specific immunocytokines augment functionality and antitumor activity of CAR-engineered NK cells

Speaker: Aline Lindner (Georg-Speyer-Haus, Frankfurt am Main, Germany)

Development of a chimeric costimulatory receptor to enhance CAR T therapy

Speaker: Dominik Lock (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes

Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

“Built-in” PD-1 Blockade: a strategy to counteract inhibition of effector cells for adoptive cell cancer therapy

Speaker: Nadia Mensali (Oslo University Hospital Radiumhospitalet, Oslo, Norway)

T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression

Speaker: Özcan Met (University Hospital Herlev, Copenhagen, Herlev, Denmark)

Donor-specific immunomodulation by clinical MIC cell infusion - a phase I study (TOL-1)

Speaker: Christian Morath (Kidney Center Heidelberg, Heidelberg, Germany)

Development of flow cytometric assays for CAR T cell manufacturing and patient immunomonitoring

Speaker: Marsilius Mues (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)

Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells

Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

Induction of tolerogenic dendritic cells in vitro by mitomycin C-induced peripheral blood mononuclear cells

Speaker: Ming Ni (University Clinic Heidelberg, Heidelberg, Germany)

In vitro expanded tumor-infiltrating lymphocytes across various sarcoma subtypes highly express LAG3 and comprise multifunctional T cells with tumor killing capacity

Speaker: Morten Nielsen (Center for Cancer Immune Therapy, Herlev University Hospital, Herlev, Denmark)

Ex vivo generation and expansion of CAR-engineered NK cells for adoptive cancer immunotherapy

Speaker: Pranav Oberoi (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

CD19 splicing and mutation linked to CART-19 immunotherapy resistance

Speaker: Claudia Paret (Medical University of Mainz, Mainz, Germany)

T Cell Receptor/DAP10 chimera as a means to attaining persistent anti-tumor T cell response

Speaker: Lourdes Plaza-Rojas (Loyola University Chicago, Maywood, United States)

Optimal-affinity T cell receptors targeting NY-ESO via MHC II help MHC I-restricted T cell receptors in tumour regression

Speaker: Lucia Poncette (Max Delbrück Center for Molecular Medicine, Berlin, Germany)

Heterogeneity and dynamics of the tumor-infiltrating lymphocyte repertoire in melanoma and pancreatic cancer patients

Speaker: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

Immunotherapy of ovarian cancer by targeting Claudin-6 with CAR-engineered T cells

Speaker: Katharina Reinhard (BioNTech Cell & Gene Therapies GmbH, Mainz, Germany)

Update on the clinical trial preparations concerning a MAGE-A1-specific T cell receptor

Speaker: Vivian Scheuplein (Max-Delbrück-Centrum, Berlin, Germany)

Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples

Speaker: Heiko Schuster (Immatics Biotechnologies GmbH, Tübingen, Germany)

TCR-pMHC 2D affinity and bond lifetime under force correlate with tumor-specific CD8 T cell responsiveness

Speaker: Julien Schmidt (University of Lausanne, Epalinges, Switzerland)

Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and modified vaccinia Ankara virus vectors

Speaker: Naveen Shridhar (University Clinic Magdeburg, Magdeburg, Germany)

How to make a fishing rod for adoptive cellular therapy: the ACTolog® approach, a multi-targeted endogenous T-cell therapy

Speaker: Stefanie Souczek (Immatics Biotechnologies GmbH, Tuebingen, Germany)

PI3K δ inhibition by idelalisib for optimized generation of CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

Speaker: Sophia Stock (University Hospital Heidelberg, Heidelberg, Germany)

Enhancing cancer immunotherapy using responsive biomaterials

Speaker: Li Tang (École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland)

Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF $^+$ T cells

Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Enhancing the activation and releasing the brakes of NK cells for treatment of Multiple Myeloma

Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Combining conventional therapy with immunotherapy: a risky business?

Speaker: Ann Vankerckhoven (KU Leuven, Leuven, Belgium)

A two chain chimeric antigen receptor (CAR) scaffold recruits T-cell endogenous CD3 subunits for physiological CAR signaling and induces efficient tumor cell killing in vitro and in vivo

Speaker: Matthias Birtel (TRON - Translational Oncology at the University Medical Center Mainz gGmbH, Mainz, Germany)

Speaker: Ralf-Holger Voss (University Medical Center (UMC) of the Johannes Gutenberg University Mainz, Mainz, Germany)

Depletion of macrophages in the tumor-draining lymph node enhances dendritic cell-induced anti-tumor immunity

Speaker: Heleen Vroman (Erasmus MC, Rotterdam, Netherlands)

Trapping TGF- β with decoy receptors restricts TGF- β mediated immune cell suppression

Speaker: Aleksandra Vuchkovska (Loyola University Chicago, Maywood, United States)

Pre-clinical validation of a TCR redirected universal NK cell line

Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

Inhibition of IL-10 secretion in CAR-engineered NK cells modulates polarization of bystander macrophages and enhances dendritic cell maturation

Speaker: Anja Waldmann (Georg-Speyer-Haus, Frankfurt, Germany)

A new cellular immunotherapy for the treatment of multiple myeloma without development of graft-versus-host disease

Speaker: Sofi Yado (Ariel University, Ariel, Israel)

Quantitative live-cell imaging as an efficient tool for the assessment of safety and efficacy of engineered T cells and bispecific molecules

Speaker: Sara Yousef (Immatics biotechnologies GmbH, Tübingen, Germany)

Preclinical characterization of an off-the-shelf chimeric antigen receptor-engineered NK cell therapeutic for adoptive cancer immunotherapy

Speaker: Congcong Zhang (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany)

Poster Session
15:30 - 18:30

East and West Foyers

Poster Session - Improving Immunity

Mouse models of pancreatic cancer for development of combinatorial immunotherapies involving cytostatic agents and agonist anti-CD40 antibody

Speaker: Daniel Baumann (German Cancer Research Center (DKFZ), Heidelberg, Germany)

Role of the Interleukin-33/ ST2L-axis for the CD8-dependent anti-cancer cytotoxicity - Protease- versus receptor-dependent regulation of Interleukin-33 bioactivity

Speaker: Caroline Dreis (Goethe University, pharmazentrum Frankfurt, Frankfurt/ Main, Germany)

Targeted immunotherapy with oncolytic measles virus vaccines

Speaker: Christine E. Engeland (National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany)

Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

Speaker: Andrew Furness (Royal Marsden NHS Foundation Trust, London, United Kingdom)

High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade

Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)

Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies

Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)

Intratumoral RNA treatment: a promising approach for the therapy of solid tumors

Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)

Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models

Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)

Abrogation of the immunosuppressive tumor microenvironment in cholangiocarcinoma by targeting PD-1 or GITR

Speaker: Jaap Kwekkeboom (Erasmus MC University Medical Center, Rotterdam, Netherlands)

Investigation of combined immune checkpoint blockade in human malignant pleural mesothelioma

Speaker: Elly Marcq (University of Antwerp, Antwerp, Belgium)

Activin-A protects against lung cancer progression by potentiating anti-tumor immunity

Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)

Rapid generation of peptide-HLA complexes with disulfide-stabilized empty HLA-A*02 molecules for high throughput screening approaches

Speaker: Andreas Moritz (Immatics biotechnologies, Tübingen, Germany)

Type I IFN responsiveness of melanoma is cell state dependent and can be both harnessed and suppressed to enhance oncolytic virotherapy efficacy

Speaker: Janne Ruotsalainen (University Hospital Magdeburg, Magdeburg, Germany)

Immunomodulatory properties of the glyco-engineered anti-EGFR antibody Tomuzotuximab

Speaker: Phillip Schiele (GlycoTope GmbH, Berlin, Germany)

dermaject® intradermal injection device ensures superficial and reproducible intradermal injections in human ex vivo skin

Speaker: Sandra Schulz (Hahn-Schickard, Villingen-Schwenningen, Germany)

Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition

Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)

Dissecting the synergistic effect of chemotherapy and immunotherapy on anti-tumoral T cell functions in breast cancer

Speaker: Lorenzo Spagnuolo (Oncode Institute, Netherland Cancer Institute, Amsterdam, Netherlands)

An improved preclinical immuno-oncology platform: Patient-derived tumor xenografts in humanized NSG-SGM3 mice

Speaker: Ralph Gareus (The Jackson Laboratory, Bar Harbor, United States)

Poster Session
15:30 - 18:30

East and West Foyers

Poster Session - New Targets & New Leads

The AA protein-based model explains how cancer could arise

Speaker: Adouda Adjiri (Setif-1 University, Setif, Algeria)

Peptide-based immune system engagers targeting $\alpha 3$ integrin prevent tumor growth and metastasis in a syngeneic triple-negative 4T1 tumor model

Speaker: Mona Ali Mahmoud Assar (University Hospital RWTH Aachen, Aachen, Germany)

Discovery and validation of highly specific T-cell receptors for Immatics's immunotherapeutic applications

Speaker: Leonie Alten (Immatics Biotechnologies GmbH, Tuebingen, Germany)

Identification and profiling of PX-D26116, a potent Hydroxyamidine-based IDO1 inhibitor

Speaker: Simon Anderhub (Phenex Pharmaceuticals AG, Heidelberg, Germany)

Nur77, a new target to boost DC vaccination?

Speaker: Marleen Ansems (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)

Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells in murine HCC

Speaker: Misbah Aslam (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer

Speaker: Richard J. Austin (Harpoon Therapeutics, South San Francisco, United States)

Identification of exceptional therapeutic anti-CD40 agonists by optimal exploitation of rabbit antibody diversity through single B-cell cloning

Speaker: Karsten Beckmann (MAB Discovery GmbH, Neuried, Germany)

Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches

Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Citrullination: a mechanism to rapidly alert the immune system to cellular stress

Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

Citrullinated peptides from self-antigens can be presented by HLA-DP4 and can be targeted for tumor therapy

Speaker: Victoria Brentville (Scancell Ltd, Nottingham, United Kingdom)

CD8+ T cell immunity against phosphopeptide neoantigens and its potential use for monitoring checkpoint inhibitor therapy

Speaker: Nico Buettner (Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany)

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients

Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)

Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity

Speaker: John Castle (Agenus Inc, Lexington, United States)

Mass spectrometry-based antigen discovery expands the cancer immunopeptidome

Speaker: Chloe Chong (Ludwig Center for Cancer Research, Epalinges, Switzerland)

Survivin, WT1 and SSX2: new targets for the immunotherapy of adult B-acute lymphoblastic leukaemia

Speaker: Leah Cooksey (The University of Hull, Hull, United Kingdom)

Cell-intrinsic and spatially distant tumor PD-L1 alters local and global anti-tumor immunity and responses to anti-PD-L1 or anti-PD-1 through novel chemokine and TIL effects

Speaker: Tyler Curiel (UT Health San Antonio, San Antonio, United States)

A novel aryl hydrocarbon receptor antagonist (PX-A24590) with anti-tumor activity in a syngeneic mouse pancreatic cancer model

Speaker: Ulrich Deuschle (Phenex Pharmaceuticals AG, Heidelberg, Germany)

Comprehensive characterization of IL-15-based tumor targeted Immunocytokines

Speaker: Laura Dix (Glycotope GmbH, Berlin, Germany)

Engineering novel antibody-based therapeutics for targeting of tumor endothelial marker 1 (TEM1)

Speaker: Julie Katrin Fierle (Ludwig Institute for Cancer Research at the University of Lausanne, Epalinges, Switzerland)

RIG-I agonist acts synergistically with PD1-checkpoint blockade as combinatorial immunotherapy in a model of hepatocellular carcinoma

Speaker: Simone Formisano (Klinikum der Universität München, Munich, Germany)

The immunopeptidomic landscape of primary versus recurrent disease in glioblastoma

Speaker: Lena Katharina Freudenmann (University of Tübingen, Interfaculty Institute for Cell Biology, Tübingen, Germany)

Tumor antigen-dependent T cell activation and tumor localization induced by a novel 4-1BB x 5T4 ADAPTIR™ bispecific antibody

Speaker: Sara Fritzell (Alligator Bioscience AB, Lund, Sweden)

Decoding the HLA immunopeptidome: Elucidating patterns of HLA allotype association and malignant cells

Speaker: Michael Ghosh (University of Tübingen, Tübingen, Germany)

Targeting the signal peptide in MMTV-associated breast cancer

Speaker: Jacob Hochman (The Hebrew University of Jerusalem, Jerusalem, Israel)

Development of an optimized scaffold for bispecific T cell receptor therapeutics

Speaker: Martin Hofmann (Immatics biotechnologies GmbH, Tuebingen, Germany)

Rapamycin and Zoledronic Acid strongly inhibit growth of advanced murine hepatocellular carcinoma via activation of innate and adaptive immunity

Speaker: Muhammad Ashfaq Khan (University Medical Center of the Johannes Gutenberg-University, Mainz, Germany)

Cytomegalovirus stimulates angiogenesis and emerges as a druggable target in glioblastoma

Speaker: Harald Krenzlin (Gutenberg-Universität Mainz, Mainz, Germany)

Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens

Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Speaker: Anne Månsson Kvarnhammar (Alligator Bioscience, Lund, Sweden)

Anticancer immunity mediated by the novel hexavalent human GITR agonist HERA-GITRL is conveyed by activating T cells without affecting Treg cells

Speaker: Viola Marschall (Apogenix AG, Heidelberg, Germany)

KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo

Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

Detection of novel citrullinated targets for cancer therapy

Speaker: Rachael Metheringham (Scancell Limited, Nottingham, United Kingdom)

Identification of receptor binding partners via APEX2 proximity labeling

Speaker: Bastian Meyer (Klinikum der Universität München, Medizinische Klinik und Poliklinik II, München, Germany)

Identification and characterization of HLA-Ligands for immunotherapeutic approaches in oropharyngeal squamous-cell carcinoma

Speaker: Lena Mühlenbruch (University of Tübingen, Tübingen, Germany)

T cells against the N345K mutation of PIK3CA

Speaker: Julia Neufeld (Johannes Gutenberg University Medical Center, Mainz, Germany)

Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade

Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)

Establishment of a human CD3ε transgenic mouse model to assess anti-tumor efficacy of human T-cell-redirecting bispecific antibodies

Speaker: Davy Xuesong Ouyang (Crown Bioscience Inc., Santa Clara, United States)

DSP106 - a novel PD1-CD70 dual signaling protein (DSP) for cancer immunotherapy

Speaker: Yehudith Jitka Sagiv (Kahr Medical Ltd, Jerusalem, Israel)

Human endogenous retroviruses as a potential reservoir for T cell mediated cancer immunotherapy

Speaker: Sunil Kumar Saini (Technical University of Denmark, Lyngby, Denmark)

Depletion of intratumoural regulatory T cells by the anti-ICOS antibody KY1044 in combination with immune checkpoint blockade enhances the anti-tumour response in pre-clinical models.

Speaker: Richard Sainson (Kymab, Cambridge, United Kingdom)

Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity

Speaker: Phillip Schiele (Glycotope GmbH, Berlin, Germany)

Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification

Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)

HERA-LIGHT, a novel hexavalent HVEM agonist promoting T cell activation and expansion

Speaker: Julian P. Sefrin (Apogenix AG, Heidelberg, Germany)

Theranostic tumor imaging of neuroblastoma using radiolabeled α CD276-antibody

Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)

Expression data integration: advancing immuno-oncology target discovery

Speaker: Frank Staubli (NEBION AG, Zurich, Switzerland)

Setup and validation of a T cell receptor maturation platform resulting in high-affinity binders for engineering of bispecific molecules

Speaker: Felix Unverdorben (Immatics biotechnologies GmbH, Tuebingen, Germany)

Tumour glycan-targeting monoclonal antibodies - Candidate immunogenic cell death inducers

Speaker: Mireille Vankemmelbeke (Scancell Ltd, Nottingham, United Kingdom)

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell non-Hodgkin lymphoma

Speaker: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)

Cloning, expression and functional characterization of an HLA-C*07:01-restricted $\alpha\beta$ T-cell receptor against chondroitin sulfate proteoglycan 4 (CSPG4)

Speaker: Catherine Wölfel (Internal Medicine III, Mainz, Germany)

GARP expressing platelets and the induction of peripheral tolerance: A novel target for anti-tumor-therapy?

Speaker: Niklas Zimmer (University Medical Center Mainz, Mainz, Germany)

Short Talk Session
15:45 - 16:15

Gutenberg Hall A

Meet the Editor

An editors guide to scientific publishing

15:45 - 16:15

Speaker: Priscilla Kelly (Science Magazine, Washington, DC, United States)

CIMT Members Meeting
17:30 - 19:00

Dijon Room

General Members Assembly of the Association for Cancer Immunotherapy CIMT

19:30 - 24:00

Foyer

Social Event & Poster Award Ceremony

Plenary Session
08:30 - 10:00

Congress Hall

Immunoguiding

Chair: Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)
Chair: Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)

Reprogramming the tumor microenvironment for efficient cancer immunotherapy **08:30 - 09:00**

Speaker: Günter J. Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Complement in cancer: untangling an intricate relationship **09:00 - 09:30**

Speaker: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

Lung cancer evolution and immune escape **09:30 - 10:00**

Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)

Break
10:00 - 10:30

Foyer

Coffee Break

Plenary Session
10:30 - 12:30

Congress Hall

Regulatory Research organized by CIMT-RRG and CARAT

Chair: Ulrich Kalinke (TWINCORE, Hanover, Germany)
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)

Chimeric antigen receptor (CAR) modified T cells - EU regulatory considerations **10:30 - 11:10**

Speaker: Martina Schüssler-Lenz (Committee for Advanced Therapies (CAT), European Medicines Agency, London, United Kingdom)

From Karl Landsteiner to CAR-T cells: from processes to products and patients **11:10 - 11:50**

Speaker: Martin Hildebrandt (Technical University Munich, Munich, Germany)

Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles **11:50 - 12:30**

Speaker: Bernd Schröder (Miltenyi Biotech, Teterow, Germany)

Short Talk Session
10:30 - 11:45

Gutenberg Hall A

Short Talk Session IV Therapeutic Vaccination

Chair: Sebastian Kreiter (TRON, Mainz, Germany)
Chair: Kris Thielemans (Vrije Universiteit Brussel, Brussels, Belgium)

Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes	10:30 - 10:45
Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)	
Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice	10:45 - 11:00
Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)	
Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors	11:00 - 11:15
Speaker: Nadja Salomon (TRON, Mainz, Germany)	
NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines	11:15 - 11:30
Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)	
Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells	11:30 - 11:45
Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)	

Short Talk Session
10:30 - 11:45

Gutenberg Hall B

Short Talk Session V Immunomonitoring

Chair: Cecile Gouttefangeas (University of Tübingen, Tübingen, Germany)
Chair: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes	10:30 - 10:45
Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)	
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival	10:45 - 11:00
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)	
Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells	11:00 - 11:15
Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)	
Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS	11:15 - 11:30
Speaker: Alexander Ulges (Immatics Biotechnologies GmbH, Tübingen, Germany)	
Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy	11:30 - 11:45
Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)	

Short Talk Session
11:45 - 13:00

Gutenberg Hall A

Short Talk Session VI Improving Immunity

Chair: Mustafa Diken (TRON, Mainz, Germany)
Chair: Onur Boyman (University Hospital Zurich, Zurich, Switzerland)

Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies	11:45 - 12:00
Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)	
Intratumoral RNA treatment: a promising approach for the therapy of solid tumors	12:00 - 12:15
Speaker: Katja Fiedler (CureVac AG, Tübingen, Germany)	
Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models	12:15 - 12:30
Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)	
Activin-A protects against lung cancer progression by potentiating anti-tumor immunity	12:30 - 12:45
Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)	
Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition	12:45 - 13:00
Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)	

Short Talk Session
11:45 - 13:00

Gutenberg Hall B

Short Talk Session VII Clinical Trials

Chair: Anthony Kong (University of Birmingham, Birmingham, United Kingdom)

Chair: Stephan Grabbe (University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients	11:45 - 12:00
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)	
CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study	12:00 - 12:15
Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)	
The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy	12:15 - 12:30
Speaker: Tracy L. Rose (Lineberger Comprehensive Cancer Center, Chapel Hill, United States)	
High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade	12:30 - 12:45
Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)	
Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade	12:45 - 13:00
Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)	

Break
13:00 - 14:00

Foyer

Lunch

Therapeutic Vaccination

Chair: Hans-Georg Rammensee (University of Tübingen, Tübingen, Germany)

Chair: Carl Figdor (Radboud University Medical Center, Nijmegen, Netherlands)

Dendritic cell-based vaccination against cancer

14:00 - 14:30

Speaker: Jolanda de Vries (Radboud University Medical Center, Nijmegen, Netherlands)

Personalized RNA vaccines

14:30 - 15:00

Speaker: Özlem Türeci (German Cluster of Individualized Immunointervention (CI3), Mainz, Germany)

Therapeutic cancer vaccine for combination with immune checkpoint blockade therapy: formulation matters

15:00 - 15:30

Speaker: Yared Hailemichael (MD Anderson Cancer Center, Houston, United States)